Korean J Gastroenterol.  2024 Nov;84(5):206-214. 10.4166/kjg.2024.106.

Non-Invasive Test for Assessment of Liver Fibrosis in Chronic Hepatitis B

• Jun YJ
• Lee M
• Chun HS
• Kim TH

• KMID: 2561590
• DOI: http://doi.org/10.4166/kjg.2024.106

Abstract

Chronic hepatitis B (CHB) is a high-risk condition that requires continuous monitoring and appropriate management during the natural course of the disease. In particular, the assessment of liver fibrosis is crucial for determining the optimal timing of antiviral therapy, evaluating the treatment response, and predicting the occurrence and prognosis of hepatocellular carcinoma (HCC) in the management of CHB. Although a liver biopsy is the gold standard for diagnosing liver inflammation, steatosis, and fibrosis, there has been a growing trend in the use of non-invasive tests, such as serum biomarkers, transient elastography, and shear wave elastography in CHB patients. This review provides a summary of the key research findings on the use of serum biomarkers and transient elastography in assessing liver fibrosis, monitoring the disease progression, and predicting the prognosis of CHB patients, with an emphasis on their clinical applicability.

Keyword

Chronic hepatitis B; Fibrosis; Liver cirrhosis; Hepatocellular carcinoma

Reference

1. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the Study of Liver Diseases. 2009; Liver biopsy. Hepatology. 49:1017–1044. DOI: 10.1002/hep.22742. PMID: 19243014.

2. Kim MN, Han JW, An J, et al. 2024; KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease. Clin Mol Hepatol. 30(Suppl):S5–S105. DOI: 10.3350/cmh.2024.0506. PMID: 39159947. PMCID: PMC11493350.

3. Korean Association for the Study of the Liver. 2012; KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 18:109–162. DOI: 10.3350/cmh.2012.18.2.109. PMID: 22893865. PMCID: PMC3415874.

4. Tang LSY, Covert E, Wilson E, Kottilil S. 2018; Chronic hepatitis B infection: A review. JAMA. 319:1802–1813. DOI: 10.1001/jama.2018.3795. PMID: 29715359.

5. Xiao G, Yang J, Yan L. 2015; Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 61:292–302. DOI: 10.1002/hep.27382. PMID: 25132233.

6. Sebastiani G, Castera L, Halfon P, et al. 2011; The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther. 34:1202–1216. DOI: 10.1111/j.1365-2036.2011.04861.x. PMID: 21981787.

7. Zhu X, Wang LC, Chen EQ, et al. 2011; Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB-4 in patients with chronic HBV infection. Dig Dis Sci. 56:2742–2749. DOI: 10.1007/s10620-011-1659-1. PMID: 21399926.

8. Jin W, Lin Z, Xin Y, Jiang X, Dong Q, Xuan S. 2012; Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol. 12:14. DOI: 10.1186/1471-230X-12-14. PMID: 22333407. PMCID: PMC3306191.

9. Salkic NN, Jovanovic P, Hauser G, Brcic M. 2014; FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Am J Gastroenterol. 109:796–809. DOI: 10.1038/ajg.2014.21. PMID: 24535095.

10. Kim BK, Kim SU, Kim HS, et al. 2012; Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One. 7:e35825. DOI: 10.1371/journal.pone.0035825. PMID: 22536445. PMCID: PMC3335013.

11. Houot M, Ngo Y, Munteanu M, Marque S, Poynard T. 2016; Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Aliment Pharmacol Ther. 43:16–29. DOI: 10.1111/apt.13446. PMID: 26516104. PMCID: PMC4737301.

12. Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, et al. 2013; A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 3:1065. DOI: 10.1038/srep01065. PMID: 23323209. PMCID: PMC3545220.

13. Nishikawa H, Takata R, Enomoto H, et al. 2017; Proposal of a predictive model for advanced fibrosis containing Wisteria floribunda agglutinin-positive Mac-2-binding protein in chronic hepatitis C. Hepatol Res. 47:E74–E84. DOI: 10.1111/hepr.12724.

14. Feng S, Wang Z, Zhao Y, Tao C. 2020; Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis. Sci Rep. 10:10582. DOI: 10.1038/s41598-020-67471-y. PMID: 32601332. PMCID: PMC7324360.

15. Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F, Poynard T. 2008; Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J Gastrointestin Liver Dis. 17:187–191.

16. Kim JH, Kim JW, Seo JW, Choe WH, Kwon SY. 2016; Noninvasive tests for fibrosis predict 5-year mortality and hepatocellular carcinoma in patients with chronic hepatitis B. J Clin Gastroenterol. 50:882–888. DOI: 10.1097/MCG.0000000000000574. PMID: 27322532.

17. Kim MN, Lee JH, Chon YE, Ha Y, Hwang SG. 2020; Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy. Eur J Gastroenterol Hepatol. 32:433–439. DOI: 10.1097/MEG.0000000000001520. PMID: 31490417.

18. Shin SK, Yim HJ, Kim JH, et al. 2021; Partial virological response after 2 years of entecavir therapy increases the risk of hepatocellular carcinoma in patients with hepatitis B virus-associated cirrhosis. Gut Liver. 15:430–439. DOI: 10.5009/gnl20074. PMID: 33115966. PMCID: PMC8129658.

19. Suh B, Park S, Shin DW, et al. 2015; High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. Hepatology. 61:1261–1268. DOI: 10.1002/hep.27654. PMID: 25502481.

20. Jeong J, Shin JW, Jung SW, Lee SB, Park EJ, Park NH. 2021; Clinical usefulness of noninvasive fibrosis indices for predicting hepatocellular carcinoma in treatment-naïve patients with chronic hepatitis B following entecavir therapy. Hepatol Res. 51:923–932. DOI: 10.1111/hepr.13690. PMID: 34224182.

21. Chiang HH, Lee CM, Hu TH, et al. 2018; A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir. Liver Int. 38:1997–2005. DOI: 10.1111/liv.13889. PMID: 29797410.

22. Liu R, Guo J, Lu Y, et al. 2019; Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy. Clin Exp Med. 19:309–320. DOI: 10.1007/s10238-019-00560-z. PMID: 31111345.

23. Li Q, Chen L, Zhou Y. 2018; Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy. Clin Exp Med. 18:273–282. DOI: 10.1007/s10238-018-0486-5. PMID: 29350286.

24. Chon YE, Kim SU, Seo YS, et al. 2022; Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. J Gastroenterol Hepatol. 37:200–207. DOI: 10.1111/jgh.15678. PMID: 34478195.

25. Dong XQ, Wu Z, Li J, Wang GQ, Zhao H. China HepB-Related Fibrosis Assessment Research Group. 2019; Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: A 78-week prospective study. J Gastroenterol Hepatol. 34:755–763. DOI: 10.1111/jgh.14498. PMID: 30290019.

26. Kim WR, Berg T, Asselah T, et al. 2016; Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 64:773–780. DOI: 10.1016/j.jhep.2015.11.012. PMID: 26626497.

27. Maimone S, Calvaruso V, Pleguezuelo M, et al. 2009; An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers. J Viral Hepat. 16:769–774. DOI: 10.1111/j.1365-2893.2009.01120.x. PMID: 19709363.

28. Chon YE, Choi EH, Song KJ, et al. 2012; Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One. 7:e44930. DOI: 10.1371/journal.pone.0044930. PMID: 23049764. PMCID: PMC3458028.

29. Li Y, Huang YS, Wang ZZ, et al. 2016; Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. Aliment Pharmacol Ther. 43:458–469. DOI: 10.1111/apt.13488. PMID: 26669632.

30. Castéra L, Bernard PH, Le Bail B, et al. 2011; Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers. Aliment Pharmacol Ther. 33:455–465. DOI: 10.1111/j.1365-2036.2010.04547.x. PMID: 21235598.

31. Oliveri F, Coco B, Ciccorossi P, et al. 2008; Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. World J Gastroenterol. 14:6154–6162. DOI: 10.3748/wjg.14.6154. PMID: 18985805. PMCID: PMC2761576.

32. Marcellin P, Ziol M, Bedossa P, et al. 2009; Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 29:242–247. DOI: 10.1111/j.1478-3231.2008.01802.x. PMID: 18637064.

33. Chan HL, Wong GL, Choi PC, et al. 2009; Alanine aminotransferasebased algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat. 16:36–44. DOI: 10.1111/j.1365-2893.2008.01037.x. PMID: 18673426.

34. Degos F, Perez P, Roche B, et al. 2010; Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 53:1013–1021. DOI: 10.1016/j.jhep.2010.05.035. PMID: 20850886.

35. Sporea I, Sirli R, Deleanu A, et al. 2010; Liver stiffness measurements in patients with HBV vs HCV chronic hepatitis: a comparative study. World J Gastroenterol. 16:4832–4837. DOI: 10.3748/wjg.v16.i38.4832. PMID: 20939112. PMCID: PMC2955253.

36. Viganò M, Paggi S, Lampertico P, et al. 2011; Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation. Aliment Pharmacol Ther. 34:353–362. DOI: 10.1111/j.1365-2036.2011.04722.x. PMID: 21631559.

37. Verveer C, Zondervan PE, ten Kate FJ, Hansen BE, Janssen HL, de Knegt RJ. 2012; Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. Liver Int. 32:622–628. DOI: 10.1111/j.1478-3231.2011.02663.x. PMID: 22098684.

38. Cardoso AC, Carvalho-Filho RJ, Stern C, et al. 2012; Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int. 32:612–621. DOI: 10.1111/j.1478-3231.2011.02660.x. PMID: 22103765.

39. Qi X, An M, Wu T, et al. 2018; Transient elastography for significant liver fibrosis and cirrhosis in chronic hepatitis B: A meta-analysis. Can J Gastroenterol Hepatol. 2018:3406789. DOI: 10.1155/2018/3406789. PMID: 29977884. PMCID: PMC5994263.

40. Mingkai L, Sizhe W, Xiaoying W, Ying L, Wu B. 2022; Diagnostic performance of elastography on liver fibrosis in antiviral treatment-naive chronic hepatitis B patients: a meta-analysis. Gastroenterol Rep (Oxf). 10:goac005. DOI: 10.1093/gastro/goac005. PMID: 35186298. PMCID: PMC8849285.

41. Boursier J, Vergniol J, Sawadogo A, et al. 2009; The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int. 29:1507–1515. DOI: 10.1111/j.1478-3231.2009.02101.x. PMID: 19725892.

42. Fraquelli M, Rigamonti C, Casazza G, et al. 2011; Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. J Hepatol. 54:621–628. DOI: 10.1016/j.jhep.2010.07.017. PMID: 21146243.

43. European Association for the Study of the Liver; Clinical Practice Guideline Panel; EASL Governing Board representative. 2021; EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 75:659–689. DOI: 10.1016/j.jhep.2021.05.025. PMID: 34166721.

44. Wong GL, Chan HL, Wong CK, et al. 2014; Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 60:339–345. DOI: 10.1016/j.jhep.2013.09.029. PMID: 24128413.

45. Seo YS, Kim MN, Kim SU, et al. 2016; Risk assessment of hepatocellular carcinoma using transient elastography vs. liver biopsy in chronic hepatitis B patients receiving antiviral therapy. Medicine (Baltimore). 95:e2985. DOI: 10.1097/MD.0000000000002985. PMID: 27015173. PMCID: PMC4998368.

46. Kim MN, Kim SU, Kim BK, et al. 2015; Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. Hepatology. 61:1851–1859. DOI: 10.1002/hep.27735. PMID: 25643638.

47. Kim BS, Seo YS, Kim YS, et al. 2018; Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis. J Gastroenterol Hepatol. 33:503–510. DOI: 10.1111/jgh.13854. PMID: 28666070.

48. Jung KS, Kim SU, Ahn SH, et al. 2011; Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 53:885–894. DOI: 10.1002/hep.24121. PMID: 21319193.

49. Jeon MY, Lee HW, Kim SU, et al. 2017; Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis. Hepatol Int. 11:268–276. DOI: 10.1007/s12072-017-9789-y. PMID: 28224351.

50. Kim DY, Song KJ, Kim SU, et al. 2013; Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. Onco Targets Ther. 6:1463–1469. DOI: 10.2147/OTT.S51986. PMID: 24204161. PMCID: PMC3804604.

51. Shin SH, Kim SU, Park JY, et al. 2015; Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. Liver Int. 35:1054–1062. DOI: 10.1111/liv.12621. PMID: 24930484.

52. Lee HW, Park SY, Lee M, et al. 2020; An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. Liver Int. 40:1736–1743. DOI: 10.1111/liv.14451. PMID: 32239602.

53. Chon HY, Lee JS, Lee HW, et al. 2022; Predictive performance of CAGE-B and SAGE-B models in Asian treatment-naive patients who started entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol. 20:e794–e807. DOI: 10.1016/j.cgh.2021.06.001. PMID: 34091048.

54. Chon HY, Lee HA, Suh SJ, et al. 2021; Addition of liver stiffness enhances the predictive accuracy of the PAGE-B model for hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 53:919–927. DOI: 10.1111/apt.16267. PMID: 33465253.

55. Lee HW, Yoo EJ, Kim BK, et al. 2014; Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Am J Gastroenterol. 109:1241–1249. DOI: 10.1038/ajg.2014.157. PMID: 24957159.

56. Chon HY, Seo YS, Lee JI, et al. 2021; Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol. 33:885–893. DOI: 10.1097/MEG.0000000000001794. PMID: 32541238.

57. Kim SU, Lee JH, Kim DY, et al. 2012; Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One. 7:e36676. DOI: 10.1371/journal.pone.0036676. PMID: 22574212. PMCID: PMC3344942.

58. Kim BK, Park YN, Kim DY, et al. 2012; Risk assessment of development of hepatic decompensation in histologically proven hepatitis B viral cirrhosis using liver stiffness measurement. Digestion. 85:219–227. DOI: 10.1159/000335430. PMID: 22414567.

59. Kim BK, Oh HJ, Park JY, et al. 2013; Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy. Liver Int. 33:180–189. DOI: 10.1111/liv.12020. PMID: 23295050.

60. Marcellin P, Gane E, Buti M, et al. 2013; Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 381:468–475. DOI: 10.1016/S0140-6736(12)61425-1. PMID: 23234725.

61. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. 2006; Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 131:1743–1751. DOI: 10.1053/j.gastro.2006.09.020. PMID: 17087951.

62. Chang TT, Liaw YF, Wu SS, et al. 2010; Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 52:886–893. DOI: 10.1002/hep.23785. PMID: 20683932.

63. Kim JH, Kim MN, Han KH, Kim SU. 2015; Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment. Liver Int. 35:1103–1115. DOI: 10.1111/liv.12628. PMID: 24976523.

64. Gou YZ, Liu B, Jiang W, Yu HT, Bai XF. 2010; The diagnostic value of ultrasound elastography in patients with hepatitis B virus infection: a prospective study. J Int Med Res. 38:2117–2125. DOI: 10.1177/147323001003800627. PMID: 21227017.

65. Enomoto M, Mori M, Ogawa T, et al. 2010; Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: Regression of liver stiffness during entecavir therapy. Hepatol Res. 40:853–861. DOI: 10.1111/j.1872-034X.2010.00687.x. PMID: 20887589.

66. Kim SU, Park JY, Kim DY, et al. 2010; Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. Hepatol Int. 4:673–680. DOI: 10.1007/s12072-010-9201-7. PMID: 21286337. PMCID: PMC2994620.

67. Wong GL, Wong VW, Choi PC, et al. 2011; On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antivir Ther. 16:165–172. DOI: 10.3851/IMP1726. PMID: 21447865.

68. Fung J, Lai CL, Cheng C, Wu R, Wong DK, Yuen MF. 2011; Mild-to-moderate elevation of alanine aminotransferase increases liver stiffness measurement by transient elastography in patients with chronic hepatitis B. Am J Gastroenterol. 106:492–496. DOI: 10.1038/ajg.2010.463. PMID: 21157442.

69. Lim SG, Cho SW, Lee YC, et al. 2011; Changes in liver stiffness measurement during antiviral therapy in patients with chronic hepatitis B. Hepatogastroenterology. 58:539–545.

70. Fung J, Lai CL, Wong DK, Seto WK, Hung I, Yuen MF. 2011; Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. J Viral Hepat. 18:e200–e205. DOI: 10.1111/j.1365-2893.2010.01428.x.

71. Ogawa E, Furusyo N, Murata M, et al. 2011; Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog. Hepatol Res. 41:1178–1188. DOI: 10.1111/j.1872-034X.2011.00869.x. PMID: 21917085.

72. Osakabe K, Ichino N, Nishikawa T, et al. 2011; Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. J Gastroenterol. 46:1324–1334. DOI: 10.1007/s00535-011-0444-4. PMID: 21822591.

73. Yan LB, Zhu X, Bai L, et al. 2013; Impact of mild to moderate elevations of alanine aminotransferase on liver stiffness measurement in chronic hepatitis B patients during antiviral therapy. Hepatol Res. 43:185–191. DOI: 10.1111/j.1872-034X.2012.01068.x. PMID: 22978384.

74. Kim MN, Kim SU, Kim BK, et al. 2014; Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. Liver Int. 34:1216–1223. DOI: 10.1111/liv.12377. PMID: 24267737.

75. Facciorusso A, Garcia Perdomo HA, Muscatiello N, Buccino RV, Wong VW, Singh S. 2018; Systematic review with meta-analysis: Change in liver stiffness during anti-viral therapy in patients with hepatitis B. Dig Liver Dis. 50:787–794. DOI: 10.1016/j.dld.2018.05.005. PMID: 29807871.

76. Xu W, Hu Q, Chen C, Li W, Li Q, Chen L. 2023; FibroScan predicts liver fibrosis progression in chronic HBV infection patients with no clear indication for antiviral therapy: A retrospective cohort study. Infect Drug Resist. 16:1777–1785. DOI: 10.2147/IDR.S402990. PMID: 37020800. PMCID: PMC10067685.

77. Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. 2013; Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination. J Gastroenterol Hepatol. 28:1842–1848. DOI: 10.1111/jgh.12327. PMID: 23829381.

78. Delle Monache M, Petrelli A, Rossi A, et al. 2021; Noninvasive evaluation of liver fibrosis in a sample of putative inactive HBV carriers in Rome, Italy. Can J Infect Dis Med Microbiol. 2021:3068690. DOI: 10.1155/2021/3068690. PMID: 34426755. PMCID: PMC8380153.